SCHEMBL6397473

SCHEMBL6397473

Clc1ccc(OC2CCN(CCNc3nc4ccccc4s3)CC2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 10/20 0.48
HRH1 P35367 10/20 0.47
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2D6 P10635 2/20 0.43
RAB9A P51151 2/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HIF1A Q16665 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
KCNH2 Q12809 6/20 0.42
CARM1 Q86X55 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397274 0.94 HRH1 (0.54) CCR3HRH1CYP1A2CYP3A4CYP2D6
SCHEMBL5185901 0.79 DRD2 (0.50) HRH1CYP1A2CYP3A4CYP2D6RAB9A
SCHEMBL6399963 0.79 CCR3 (0.48) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL27645228 0.77 SCD (0.58) CCR3HRH1CYP1A2CYP2D6RAB9A
SCHEMBL6398460 0.77 CCR3 (0.54) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL6396602 0.76 CCR3 (0.47) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL6398399 0.75 CCR3 (0.56) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL7596643 0.74 HRH1 (0.48) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL6403204 0.74 CCR3 (0.53) CCR3HRH1KCNH2CARM1PRMT6
SCHEMBL491904 0.74 ILK (0.58) CYP1A2CYP3A4CYP2D6RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030134840-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2003-07-17 US claimed
JP-2002540204-A 2002-11-26 JP claimed
CN-1344266-A Novel compounds ASTRAZENECA AB (SE) 2002-04-10 CN claimed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP claimed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO claimed
US-6946478-B2 Compounds ASTRAZENECA AB (SE) 2005-09-20 US disclosed
US-20030134840-A1 Novel compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2003-07-17 US disclosed
US-6518286-B1 Piperidinyl compounds for modulation of immune and inflammatory responses in various diseases and disorders, including asthma ASTRAZENECA AB (SE) 2003-02-11 US disclosed
CN-1344266-A Novel compounds ASTRAZENECA AB (SE) 2002-04-10 CN disclosed
EP-1165545-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2002-01-02 EP disclosed
WO-2000058305-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134840-A1 Novel compounds RPS4X, RPS4Y1, CYP4B1 CCR3 894/4885HRH1 802/4885CYP1A2 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.